Dr Zaklina Kovacevic

Postdoctoral Researcher
Pathology
Sydney Medical School


Map

Keywords

Cancer

Selected grants

2014

  • CLARIOstar Multifunctional Microplate Reader for Shared Used at the Open Access, Multi-User Molecular Biology Core Facility; Huang M, Scolyer R, Fraser S, Sahni S, Speranza T, Owens T, Barrs V, Ju Y, Kovacevic Z, Lu Z, Camp A, Slobedman B, Morris B, Oliver B, Dos Remedios C, Kalinowski D, Fu D, Lai D, Lovicu F, Allbutt H, Triccas J, Burgess J, Kril J, Dixon K, Rendina L, Byrne M, King N, Groundwater P, Williamson P, Ho J, Dong Q, Bao B, Assinder S, McLennan S, Richardson D, Ammit A, Sharland A, Hardikar A, Hong A, Hambly B, Lee C, Murphy C, Goldsbury C, Johnstone D, Lane D, Hibbs D, Joshua D, Huq F, Halliday G, Sutherland G, Zreiqat H, Lok H, Lyons G, Jansson P, Black J, Zhu L, Sunde M, Day M, Naylor M, Buckland M, Murray M, Shafie N, Lay P, Poronnik P, Codd R, Mason R, Ryan R, Christopherson R, de Graaf S; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Pharmacological Targeting of Integrated Oncogenic and Tumour Suppressive Pathways using Novel Therapeutics; Richardson D, Kovacevic Z, Kalinowski D; National Health and Medical Research Council (NHMRC)/Project Grants.

2013

  • Robotic High Throughput Western Analysis for the Open Access, Multi-User Sydney Cancer Research Core Facility; Richardson D, Scolyer R, Boyer M, Halliday G, Damian D, Christopherson R, Joshua D, Kench J, Hong A, Murray M, Lee C, Kalinowski D, Naylor M, Lay P, Lyons G, Kovacevic Z, Mason R, Dixon K, Chan-Ling T, Hawkins C, Sunde M, Lovejoy D, Owens T, Rendina L, Jansson P, Dos Remedios C, Charles (nee Slaviero) K, Lane D, Witting P, Dong Q, Ammit A, Groundwater P, Assinder S, Bao B, Byrne S, Zhou F, Buckland M, Grewal T, Huq F, Lai D, Codd R, Zhang D, Fu D, de Graaf S, Huang M, Payne R, Slobedman B, Barrs V, Ho J, Williamson P, Murphy C; DVC Research/Equipment Grant.
  • Targeting the Metastasis Suppressor NDRG1 for the Treatment of Pancreatic Cancer.; Kovacevic Z; Cancer Institute New South Wales/Early Career Development Fellowship.
  • QX100 Droplet Digital PCR system for Shared Used at the Open Access, Multi-User Molecular Biology Core Facility; Richardson D, Kril J, Murphy C, Vandenberg R, Rendina L, Dos Remedios C, Ju Y, Kovacevic Z, Lyons G, Sutherland G, Lay P, Ammit A, Lai D, Morris B, Day M, Dong Q, Bao B, Huang M, Camp A, Boyer M, Whittington R, Byrne M, Hanrahan J, Fu D, Jansson P, Lane D, Bagley E, Hibbs D, Zhang D, Fraser S, Scolyer R, Black J, Halliday G, Christie M, Zreiqat H, Murray M, Slobedman B, Naylor M, Burgess J, Triccas J, Mason R, Chadban S, Combes V, Lovicu F, McLennan S, Kalinowski D, Sharland A, Johnstone D, Groundwater P, Dixon K, Zhou F, Lovejoy D, Lu Z, Zhu L, Goldsbury C, Witting P, Buckland M, Assinder S, Purdie (Williams) A, Codd R, Owens T, Hambly B; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2012

  • A new treatment strategy for pancreatic cancer; Richardson D, Kovacevic Z; National Health and Medical Research Council (NHMRC)/Early Career Fellowships (ECF).
  • GeneAtlas Personal Microarray System; Richardson D, Scolyer R, Stocker R, Weninger W, Black J, Allen D, Murray M, Mason R, Twigg S, King N, Horvath L, Lovicu F, Lee C, Halliday G, Lovejoy D, Joshua D, Sharland A, Roufogalis B, Hambly B, Morris B, Bao B, Bishop A, Hibbs D, Lane D, Zhou F, Hanrahan J, Dixon K, Rendina L, Byrne M, Naylor M, Cole N, Jansson P, Dong Q, Codd R, Payne R, Assinder S, Chadban S, Fraser S, McLennan S, Suryo Rahmanto A, Lai D, Yu Y, Ju Y, Buckland M, Kovacevic Z, Saletta F, Zreiqat H, Kalinowski D, Groundwater P, Simes R, Zhang D, Boyer M, Murphy C; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2011

  • PyroMark Q96 ID system; Richardson D, Stone J, Black J, King N, Mason R, Hunt N, Kril J, Murray M, Scolyer R, Halliday G, Vandenberg R, McMinn P, Chadban S, Byrne M, Ryan R, Dong Q, Lee C, Bishop A, Haass N, Fraser S, Hambly B, Sharland A, Kalinowski D, Assinder S, Yu Y, Bao B, Ju Y, Lovejoy D, Buckland M, Lane D, Dos Remedios C, Kovacevic Z, Sutherland G, Zhang D, Morris B, Suryo Rahmanto A, Murphy C; National Health and Medical Research Council (NHMRC)/Equipment Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Lane, D., Mills, T., Shafie, N., Merlot, A., Saleh Moussa, R., Kalinowski, D., Kovacevic, Z., Richardson, D. (2014). Expanding horizons in iron chelation and the treatment of cancer: Role of iron in the regulation of ER stress and the epithelial-mesenchymal transition. Biochimica et Biophysica Acta-Reviews on Cancer, 1845 (2), 166-181. [More Information]
  • Fang, B., Kovacevic, Z., Park, K., Kalinowski, D., Jansson, P., Lane, D., Sahni, S., Richardson, D. (2014). Molecular Functions of the Iron-Regulated Metastasis Suppressor, NDRG1, and its Potential as a Molecular Target for Cancer Therapy. Biochimica et Biophysica Acta (Molecular and Cell Biology of Lipids), 1845 (1), 1-19. [More Information]
  • Sahni, S., Bae, D., Lane, D., Kovacevic, Z., Kalinowski, D., Jansson, P., Richardson, D. (2014). The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells. The Journal of Biological Chemistry, 289(14), 9692-9709. [More Information]
  • Dixon, K., Lui, G., Kovacevic, Z., Zhang, D., Yao, M., Chen, Z., Dong, Q., Assinder, S., Richardson, D. (2013). Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. British Journal of Cancer, 108(2), 409-419. [More Information]
  • Richardson, A., Kovacevic, Z., Richardson, D. (2013). Iron Chelation: Inhibition of Key Signaling Pathways in the Induction of the Epithelial Mesenchymal Transition in Pancreatic Cancer and Other Tumors. Critical Reviews in Oncogenesis, 18(5), 409-434. [More Information]
  • Sun, J., Zhang, D., Bae, D., Sahni, S., Jansson, P., Zheng, Y., Zhao, Q., Yue, F., Zheng, M., Kovacevic, Z., Richardson, D. (2013). Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. Carcinogenesis, 34(9), 1943-1954. [More Information]
  • Lane, D., Saletta, F., Suryo Rahmanto, Y., Kovacevic, Z., Richardson, D. (2013). N-myc Downstream Regulated 1 (NDRG1) Is Regulated by Eukaryotic Initiation Factor 3a (eIF3a) during Cellular Stress Caused by Iron Depletion. PLoS One, 8(2), 1-15. [More Information]
  • Sun, J., Zhang, D., Zheng, Y., Zhao, Q., Zheng, M., Kovacevic, Z., Richardson, D. (2013). Targeting the Metastasis Suppressor, NDRG1, Using Novel Iron Chelators: Regulation of Stress Fiber-Mediated Tumor Cell Migration via Modulation of the ROCK1/pMLC2 Signaling Pathway. Molecular Pharmacology, 83(2), 454-469. [More Information]
  • Lui, G., Obeidy, P., Ford, S., Tselepis, C., Sharp, D., Jansson, P., Kalinowski, D., Kovacevic, Z., Lovejoy, D., Richardson, D. (2013). The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action. Molecular Pharmacology, 83(1), 179-190. [More Information]
  • Kovacevic, Z., Chikhani, S., Lui, G., Sivagurunathan, S., Richardson, D. (2013). The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways. Antioxidants & Redox Signaling, 18(8), 874-887. [More Information]
  • Kalinowski, D., Jansson, P., Kovacevic, Z., Richardson, D. (2013). The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism. Redox Report, 18(2), 48-50. [More Information]
  • Bae, D., Jansson, P., Huang, M., Kovacevic, Z., Kalinowski, D., Lee, C., Sahni, S., Richardson, D. (2013). The role of NDRG1 in the pathology and potential treatment of human cancers. Journal of Clinical Pathology, 66(11), 911-917. [More Information]
  • Yu, Y., Gutierrez, E., Kovacevic, Z., Saletta, F., Obeidy, P., Suryo Rahmanto, Y., Richardson, D. (2012). Iron chelators for the treatment of cancer. Current Medicinal Chemistry, 19(17), 2689-2702. [More Information]
  • Correnti, C., Richardson, V., Sia, A., Bandaranayake, A., Ruiz, M., Suryo Rahmanto, Y., Kovacevic, Z., Clifton, M., Holmes, M., Kaiser, B., Richardson, D., et al (2012). Siderocalin/Lcn2/NGAL/24p3 Does Not Drive Apoptosis Through Gentisic Acid Mediated Iron Withdrawal in Hematopoietic Cell Lines. PLoS One, 7(8), 1-15. [More Information]
  • Serda, M., Kalinowski, D., Mrozek-Wilczkiewicz, A., Musiol, R., Szurko, A., Ratuszna, A., Pantarat, N., Kovacevic, Z., Merlot, A., Richardson, D., et al (2012). Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy. Bioorganic & Medicinal Chemistry Letters, 22(17), 5527-5531. [More Information]
  • Kovacevic, Z., Richardson, D. (2012). Targeting Iron in Cancer Cells: A New Strategy to Inhibit Metastatic Progression. Vitamins & Trace Elements, 1(3), 1-2. [More Information]
  • Chen, Z., Zhang, D., Yue, F., Zheng, M., Kovacevic, Z., Richardson, D. (2012). The iron chelators Dp44mT and DFO inhibit TGF-B-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). Journal of Biological Chemistry, 287(21), 17016-17028. [More Information]
  • Kovacevic, Z., Yu, Y., Richardson, D. (2011). Chelators to the rescue: different horses for different courses!. Chemical Research in Toxicology, 24(3), 279-282. [More Information]
  • Saletta, F., Kovacevic, Z., Richardson, D. (2011). Iron chelation: deciphering novel molecular targets for cancer therapy. The tip of the iceberg of a web of iron-regulated molecules. Future Medicinal Chemistry, 3(16), 1983-1986. [More Information]
  • Kovacevic, Z., Chikhani, S., Lovejoy, D., Richardson, D. (2011). Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A new Strategy for the Treatment of Pancreatic Cancer. Molecular Pharmacology, 80(4), 598-609. [More Information]
  • Kovacevic, Z., Kalinowski, D., Lovejoy, D., Yu, Y., Suryo Rahmanto, Y., Sharpe, P., Bernhardt, P., Richardson, D. (2011). The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer. Current Topics in Medicinal Chemistry, 11(5), 483-499. [More Information]
  • Kovacevic, Z., Sivagurunathan, S., Mangs, A., Chikhani, S., Zhang, D., Richardson, D. (2011). The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis, 32(5), 732-740. [More Information]
  • Mrozek-Wilczkiewicz, A., Kalinowski, D., Musiol, R., Finster, J., Szurko, A., Serafin, K., Knas, M., Kamalapuram, S., Kovacevic, Z., Jampilek, J., Richardson, D., et al (2010). Investigating the anti-proliferative activity of styrylazanaphthalenes and azanaphthalenediones. Bioorganic and Medicinal Chemistry, 18(7), 2664-2671. [More Information]
  • Otevrel, J., Mandelova, Z., Pesko, M., Guo, J., Kralova, K., Sersen, F., Vejsova, M., Kalinowski, D., Kovacevic, Z., Coffey, A., Richardson, D., et al (2010). Investigating the Spectrum of Biological Activity of Ring-Substituted Salicylanilides and Carbamoylphenylcarbamates. Molecules, 15(11), 8122-8142. [More Information]
  • Kovacevic, Z., Kalinowski, D., Lovejoy, D., Quach, P., Burn (Wong), J., Richardson, D. (2010). Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity. Current Drug Delivery, 7(3), 194-207. [More Information]
  • Assinder, S., Dong, Q., Kovacevic, Z., Richardson, D. (2009). The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochemical Journal, 417(2), 411-421. [More Information]
  • Yu, Y., Kalinowski, D., Kovacevic, Z., Siafakas, A., Jansson, P., Stefani, C., Lovejoy, D., Sharpe, P., Bernhardt, P., Richardson, D. (2009). Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors. Journal of Medicinal Chemistry, 52(17), 5271-5294. [More Information]
  • Kovacevic, Z., Fu, D., Richardson, D. (2008). The iron-regulated metastasis suppressor, Ndrg-1: Identification of novel molecular targets. BBA: Biochimica et Biophysica Acta - Molecular Cell Research, 1783 (10), 1981-1992. [More Information]
  • Yu, Y., Kovacevic, Z., Richardson, D. (2007). Tuning Cell Cycle Regulation With an Iron Key. Cell Cycle, 6(16), 1982-1994. [More Information]
  • Kovacevic, Z., Richardson, D. (2006). The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis, 27(12), 2355-2366. [More Information]

2014

  • Lane, D., Mills, T., Shafie, N., Merlot, A., Saleh Moussa, R., Kalinowski, D., Kovacevic, Z., Richardson, D. (2014). Expanding horizons in iron chelation and the treatment of cancer: Role of iron in the regulation of ER stress and the epithelial-mesenchymal transition. Biochimica et Biophysica Acta-Reviews on Cancer, 1845 (2), 166-181. [More Information]
  • Fang, B., Kovacevic, Z., Park, K., Kalinowski, D., Jansson, P., Lane, D., Sahni, S., Richardson, D. (2014). Molecular Functions of the Iron-Regulated Metastasis Suppressor, NDRG1, and its Potential as a Molecular Target for Cancer Therapy. Biochimica et Biophysica Acta (Molecular and Cell Biology of Lipids), 1845 (1), 1-19. [More Information]
  • Sahni, S., Bae, D., Lane, D., Kovacevic, Z., Kalinowski, D., Jansson, P., Richardson, D. (2014). The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells. The Journal of Biological Chemistry, 289(14), 9692-9709. [More Information]

2013

  • Dixon, K., Lui, G., Kovacevic, Z., Zhang, D., Yao, M., Chen, Z., Dong, Q., Assinder, S., Richardson, D. (2013). Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. British Journal of Cancer, 108(2), 409-419. [More Information]
  • Richardson, A., Kovacevic, Z., Richardson, D. (2013). Iron Chelation: Inhibition of Key Signaling Pathways in the Induction of the Epithelial Mesenchymal Transition in Pancreatic Cancer and Other Tumors. Critical Reviews in Oncogenesis, 18(5), 409-434. [More Information]
  • Sun, J., Zhang, D., Bae, D., Sahni, S., Jansson, P., Zheng, Y., Zhao, Q., Yue, F., Zheng, M., Kovacevic, Z., Richardson, D. (2013). Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. Carcinogenesis, 34(9), 1943-1954. [More Information]
  • Lane, D., Saletta, F., Suryo Rahmanto, Y., Kovacevic, Z., Richardson, D. (2013). N-myc Downstream Regulated 1 (NDRG1) Is Regulated by Eukaryotic Initiation Factor 3a (eIF3a) during Cellular Stress Caused by Iron Depletion. PLoS One, 8(2), 1-15. [More Information]
  • Sun, J., Zhang, D., Zheng, Y., Zhao, Q., Zheng, M., Kovacevic, Z., Richardson, D. (2013). Targeting the Metastasis Suppressor, NDRG1, Using Novel Iron Chelators: Regulation of Stress Fiber-Mediated Tumor Cell Migration via Modulation of the ROCK1/pMLC2 Signaling Pathway. Molecular Pharmacology, 83(2), 454-469. [More Information]
  • Lui, G., Obeidy, P., Ford, S., Tselepis, C., Sharp, D., Jansson, P., Kalinowski, D., Kovacevic, Z., Lovejoy, D., Richardson, D. (2013). The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action. Molecular Pharmacology, 83(1), 179-190. [More Information]
  • Kovacevic, Z., Chikhani, S., Lui, G., Sivagurunathan, S., Richardson, D. (2013). The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways. Antioxidants & Redox Signaling, 18(8), 874-887. [More Information]
  • Kalinowski, D., Jansson, P., Kovacevic, Z., Richardson, D. (2013). The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism. Redox Report, 18(2), 48-50. [More Information]
  • Bae, D., Jansson, P., Huang, M., Kovacevic, Z., Kalinowski, D., Lee, C., Sahni, S., Richardson, D. (2013). The role of NDRG1 in the pathology and potential treatment of human cancers. Journal of Clinical Pathology, 66(11), 911-917. [More Information]

2012

  • Yu, Y., Gutierrez, E., Kovacevic, Z., Saletta, F., Obeidy, P., Suryo Rahmanto, Y., Richardson, D. (2012). Iron chelators for the treatment of cancer. Current Medicinal Chemistry, 19(17), 2689-2702. [More Information]
  • Correnti, C., Richardson, V., Sia, A., Bandaranayake, A., Ruiz, M., Suryo Rahmanto, Y., Kovacevic, Z., Clifton, M., Holmes, M., Kaiser, B., Richardson, D., et al (2012). Siderocalin/Lcn2/NGAL/24p3 Does Not Drive Apoptosis Through Gentisic Acid Mediated Iron Withdrawal in Hematopoietic Cell Lines. PLoS One, 7(8), 1-15. [More Information]
  • Serda, M., Kalinowski, D., Mrozek-Wilczkiewicz, A., Musiol, R., Szurko, A., Ratuszna, A., Pantarat, N., Kovacevic, Z., Merlot, A., Richardson, D., et al (2012). Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy. Bioorganic & Medicinal Chemistry Letters, 22(17), 5527-5531. [More Information]
  • Kovacevic, Z., Richardson, D. (2012). Targeting Iron in Cancer Cells: A New Strategy to Inhibit Metastatic Progression. Vitamins & Trace Elements, 1(3), 1-2. [More Information]
  • Chen, Z., Zhang, D., Yue, F., Zheng, M., Kovacevic, Z., Richardson, D. (2012). The iron chelators Dp44mT and DFO inhibit TGF-B-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). Journal of Biological Chemistry, 287(21), 17016-17028. [More Information]

2011

  • Kovacevic, Z., Yu, Y., Richardson, D. (2011). Chelators to the rescue: different horses for different courses!. Chemical Research in Toxicology, 24(3), 279-282. [More Information]
  • Saletta, F., Kovacevic, Z., Richardson, D. (2011). Iron chelation: deciphering novel molecular targets for cancer therapy. The tip of the iceberg of a web of iron-regulated molecules. Future Medicinal Chemistry, 3(16), 1983-1986. [More Information]
  • Kovacevic, Z., Chikhani, S., Lovejoy, D., Richardson, D. (2011). Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A new Strategy for the Treatment of Pancreatic Cancer. Molecular Pharmacology, 80(4), 598-609. [More Information]
  • Kovacevic, Z., Kalinowski, D., Lovejoy, D., Yu, Y., Suryo Rahmanto, Y., Sharpe, P., Bernhardt, P., Richardson, D. (2011). The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer. Current Topics in Medicinal Chemistry, 11(5), 483-499. [More Information]
  • Kovacevic, Z., Sivagurunathan, S., Mangs, A., Chikhani, S., Zhang, D., Richardson, D. (2011). The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis, 32(5), 732-740. [More Information]

2010

  • Mrozek-Wilczkiewicz, A., Kalinowski, D., Musiol, R., Finster, J., Szurko, A., Serafin, K., Knas, M., Kamalapuram, S., Kovacevic, Z., Jampilek, J., Richardson, D., et al (2010). Investigating the anti-proliferative activity of styrylazanaphthalenes and azanaphthalenediones. Bioorganic and Medicinal Chemistry, 18(7), 2664-2671. [More Information]
  • Otevrel, J., Mandelova, Z., Pesko, M., Guo, J., Kralova, K., Sersen, F., Vejsova, M., Kalinowski, D., Kovacevic, Z., Coffey, A., Richardson, D., et al (2010). Investigating the Spectrum of Biological Activity of Ring-Substituted Salicylanilides and Carbamoylphenylcarbamates. Molecules, 15(11), 8122-8142. [More Information]
  • Kovacevic, Z., Kalinowski, D., Lovejoy, D., Quach, P., Burn (Wong), J., Richardson, D. (2010). Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity. Current Drug Delivery, 7(3), 194-207. [More Information]

2009

  • Assinder, S., Dong, Q., Kovacevic, Z., Richardson, D. (2009). The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochemical Journal, 417(2), 411-421. [More Information]
  • Yu, Y., Kalinowski, D., Kovacevic, Z., Siafakas, A., Jansson, P., Stefani, C., Lovejoy, D., Sharpe, P., Bernhardt, P., Richardson, D. (2009). Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors. Journal of Medicinal Chemistry, 52(17), 5271-5294. [More Information]

2008

  • Kovacevic, Z., Fu, D., Richardson, D. (2008). The iron-regulated metastasis suppressor, Ndrg-1: Identification of novel molecular targets. BBA: Biochimica et Biophysica Acta - Molecular Cell Research, 1783 (10), 1981-1992. [More Information]

2007

  • Yu, Y., Kovacevic, Z., Richardson, D. (2007). Tuning Cell Cycle Regulation With an Iron Key. Cell Cycle, 6(16), 1982-1994. [More Information]

2006

  • Kovacevic, Z., Richardson, D. (2006). The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis, 27(12), 2355-2366. [More Information]

To update your profile click here. For support on your academic profile contact .